252 related articles for article (PubMed ID: 26352111)
41. Method comparison of three serum free light chain assays on the Roche Cobas 6000 c501 chemistry analyzer.
Augustijn D; Jacobs JFM; Russcher H
Clin Chem Lab Med; 2022 Feb; 60(3):379-385. PubMed ID: 34969184
[TBL] [Abstract][Full Text] [Related]
42. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool.
Campbell JP; Heaney JL; Shemar M; Baldwin D; Griffin AE; Oldridge E; Goodall M; Afzal Z; Plant T; Cobbold M; Jefferis R; Jacobs JF; Hand C; Drayson MT
Clin Chem Lab Med; 2017 Mar; 55(3):424-434. PubMed ID: 27505089
[TBL] [Abstract][Full Text] [Related]
43. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
[TBL] [Abstract][Full Text] [Related]
44. Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.
Sabatino R; Perrone A; Cuomo M; Liotti S; Barchiesi V; Cantile M; Cavalcanti E
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417905
[TBL] [Abstract][Full Text] [Related]
45. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
[TBL] [Abstract][Full Text] [Related]
46. Method comparison of four clinically available assays for serum free light chain analysis.
Fleming CKA; Swarttouw T; de Kat Angelino CM; Jacobs JFM; Russcher H
Clin Chem Lab Med; 2019 Dec; 58(1):85-94. PubMed ID: 31730518
[TBL] [Abstract][Full Text] [Related]
47. Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease.
Yang Y; Han X; Zheng G; Cai Z
Health Sci Rep; 2019 Apr; 2(4):e113. PubMed ID: 31049418
[TBL] [Abstract][Full Text] [Related]
48. Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies.
Holding S; Spradbery D; Hoole R; Wilmot R; Shields ML; Levoguer AM; Doré PC
Clin Chem Lab Med; 2011 Jan; 49(1):83-8. PubMed ID: 20961192
[TBL] [Abstract][Full Text] [Related]
49. Quantification of Free Immunoglobulin Light Chains in Urine.
Singh G; Cotter T; Ye Mon M; Xu H; Bollag RJ
J Appl Lab Med; 2023 Nov; 8(6):1101-1114. PubMed ID: 37725944
[TBL] [Abstract][Full Text] [Related]
50. Limitations of Free Light Chain Assays caused by the Matrix Effect.
Farnsworth CW; Logsdon NM; Hayes JE; Rais R; Willrich MA; Gronowski AM
J Appl Lab Med; 2020 Mar; 5(2):311-319. PubMed ID: 32445382
[TBL] [Abstract][Full Text] [Related]
51. Detection of free light chain monoclonal proteins co-migrating with intact monoclonal proteins in patients with monoclonal gammopathy.
Wetenhall K; Saleem R; Rowbottom A
Ann Clin Biochem; 2012 Nov; 49(Pt 6):603-5. PubMed ID: 22949729
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis.
Mollee P; Tate J; Pretorius CJ
Clin Chem Lab Med; 2013 Dec; 51(12):2303-10. PubMed ID: 23934643
[TBL] [Abstract][Full Text] [Related]
53. Complementarily of urine analysis and serum free light chain assay for assessing response treatment response: illustrated by three case examples.
Levinson SS
Clin Chim Acta; 2011 Nov; 412(23-24):2206-10. PubMed ID: 21864518
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
Vermeersch P; Van Hoovels L; Delforge M; Mariën G; Bossuyt X
Br J Haematol; 2008 Nov; 143(4):496-502. PubMed ID: 18729849
[TBL] [Abstract][Full Text] [Related]
55. [Free light chains assay: Indications and methods].
Martellosio JP; Leleu X; Roblot P; Martin M; Puyade M
Rev Med Interne; 2019 May; 40(5):297-305. PubMed ID: 30862366
[TBL] [Abstract][Full Text] [Related]
56. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
57. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.
Katzmann JA; Dispenzieri A; Kyle RA; Snyder MR; Plevak MF; Larson DR; Abraham RS; Lust JA; Melton LJ; Rajkumar SV
Mayo Clin Proc; 2006 Dec; 81(12):1575-8. PubMed ID: 17165636
[TBL] [Abstract][Full Text] [Related]
58. Urine immunofixation electrophoresis remains important and is complementary to serum free light chain.
Levinson SS
Clin Chem Lab Med; 2011 Nov; 49(11):1801-4. PubMed ID: 21663562
[TBL] [Abstract][Full Text] [Related]
59. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
Akar H; Seldin DC; Magnani B; O'Hara C; Berk JL; Schoonmaker C; Cabral H; Dember LM; Sanchorawala V; Connors LH; Falk RH; Skinner M
Amyloid; 2005 Dec; 12(4):210-5. PubMed ID: 16399645
[TBL] [Abstract][Full Text] [Related]
60. Measurement of free light chains with assays based on monoclonal antibodies.
Te Velthuis H; Drayson M; Campbell JP
Clin Chem Lab Med; 2016 Jun; 54(6):1005-14. PubMed ID: 27010775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
